This landmark study aims to improve the treatment of patients receiving end-of-life care and lead to a more uniform approach and consistent management within the NHS.
The trial will assess the overall effectiveness and cost-effectiveness ofclinically-assistedhydration in reducing the frequency of delirium and its effect on the frequency of pain and other symptoms such as shortness of breath, nausea andvomiting.
The trial is managed by Surrey Clinical Trials Unit (CTU); the trial will be the largest everperformed, andwill involve 1600 patients in 80 hospices andhospitals across the UK.
